Why I’m tempted to buy GlaxoSmithKline (LON: GSK) stock now, after all these years!

I reckon GlaxoSmithKline’s (LON: GSK) new focus on R&D-driven healthcare could build value for shareholders in the years to come.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) is a huge FTSE 100 stock that City analysts analyse to pieces. That’s why the share research website I use lists some 27 brokers covering the company.

A consensus regarding GlaxoSmithKline stock

And recently, 16 of those brokers have the stock as a hold, 7 as a buy, 4 as a strong buy, and 2 as a sell. But although having that information is helpful, analysts are frequently behind the curve or plain wrong. Therefore, the best course of action is for me to always do my own research and make my own decisions.

For my portfolio, I’ve had GlaxoSmithKline on a watch list for years. And my most recent note about the stock reads, “Looking for a breakout from the current base”. It bears the date 20 April 2018 — and until now, I’ve still been waiting for that condition before buying!

To me, a breakout means a sudden improvement in operational progress that will likely reflect in better revenues, earnings, cash flow, shareholder dividends, and a rising share price. My aim would be to buy the stock when the share price begins a hopefully longer move higher.

But the business has been treading water for a long time. And I reckon the best indicator of that is the record of shareholder dividends. In 2015, the total payout for the year was 80p per share. And it’s been 80p ever since, although it is set to decline — read on.

In fairness, that’s not bad. With the share price near 1,454p, the yield has been around 5.5%. So, if I’d followed the analysts’ consensus and held GlaxoSmithKline shares for the past six years or so, I’d have achieved a decent return. And that’s especially true because of the sideways progress of the share price over the period.

But for me, a dividend-led investment requires a record of annual incremental rises in the dividend with improving fundamentals to back that up. Sadly, the business has failed to deliver.

The business is in flux

However, the company is in a state of flux as it prepares to de-merge its consumer healthcare operations in mid-2022, which will likely lead to a decline in dividends from the remaining business. Chief executive Emma Walmsley said in today’s third-quarter results report that she’s confident in the outlook for “a step-change in growth and performance in 2022 and beyond”.

In the third quarter and at constant exchange rates, sales rose 10% year on year with adjusted earnings per share rising 3%. Walmsley reckons behind those figures, the business delivered double-digit sales growth in Pharmaceuticals and Vaccines, increased momentum in Consumer Healthcare, and continued discipline on costs”.

Looking ahead, GlaxoSmithKline expects earnings to decline by between 2% and 4% for the full trading year 2021. But that estimate excludes any contribution from Covid-19 solutions. The guidance does represent an upgrade from previous expectations.

I think the consensus of City analysts’ opinions has been correct, and the stock has been a good hold. But I also think the de-merger and GlaxoSmithKline’s new focus on R&D-driven healthcare could build value for shareholders in the years to come, although nothing is certain. Indeed, all shares carry risks and the firm’s plans may not work out as expected. Nevertheless, I’m tempted to buy the stock now to see if growth reboots.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Road 2025 to 2032 new year direction concept
Investing Articles

With interest rates falling, dividend stocks could be the key to passive income between now and 2030

In the years ahead, dividend stocks are likely to offer far more potential for passive income than savings accounts, says…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Which is better: £100,000 or a second income of £5,481 per year?

Dividend stocks and government bonds are both worthy ways of earning a second income. But which is a better choice…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

After a 15% decline, should I move on from this FTSE 100 stock?

An investment in a FTSE 100 restructuring situation isn’t going the way our author had anticipated. Should he sit tight,…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Investing Articles

If a 30-year-old puts £500 a month into a Stocks and Shares ISA, they could have £2.3m at retirement!

Starting early, picking wisely and investing £500 a month from age 30 might just lead to a multi-million-pound Stocks and…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Here’s what needs to happen for the Lloyds share price to reach £1

The Lloyds share price is up 40% since the start of the year, but could it continue to climb all…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

Here’s how investing £10,000 a year can lead to annual passive income of £67,000

This writer explores two different stock market approaches to building up a sizeable passive income figure. Both can generate significant…

Read more »

Senior woman potting plant in garden at home
Investing Articles

Start putting £700 each month into a SIPP to try and retire as a millionaire!

By investing £700 a month using a SIPP, even someone in their 40s with no savings might retire a millionaire.…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

Move over premium bonds: here’s how to earn passive income on the stock market

Premium bonds may have been good to some Britons, but the average yield is far below what most passive income…

Read more »